



21st September 2009

Companies Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT / MEDIA RELEASE

ANTEO DIAGNOSTICS LIMITED (ASX:ADO) (“ANTEO” or “THE COMPANY”) REPLACEMENT ENTITLEMENT ISSUE PROSPECTUS

The Company, on Friday 18th September 2009 lodged with ASX an Entitlement Issue Prospectus document. Unfortunately the Company’s Australian Business Number (“ABN”) was misquoted on the front cover, and at page 31 of that document.

Accordingly the Company now provides a replacement Entitlement Issue Prospectus document with the corrected ABN.

For further information please contact:

Dr Geoff Cumming, CEO, Anteo Diagnostics Limited

Tel: +612 8823 3110

Mr James Henderson, Non Executive Chairman, Anteo Diagnostics Limited

Tel: +612 8823 3100

About Anteo

Anteo Diagnostics is an Australian company that specializes in the design and assembly of multi-component coatings for the solid phase of immunoassays and the use of those coatings in biomarker development. Anteo’s proprietary coatings bind, orient and protect proteins such as antibodies in specific ways that enhance functionality. This results in dramatically improved immunoassay performance such as better sensitivity, and cost savings such as batch-to-batch reproducibility. Anteo applies its coatings to develop novel biomarkers for a range of diseases. Anteo works with many types of solid phase materials and formats, like beads of different kinds, membranes and plates. For more information, visit www.anteodx.com

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com

For personal use only